Krishnan Krish S

Krishnan Krish S, President and CEO of Krystal Biotech (KRYS), has demonstrated a consistent pattern of selling company shares, with no recorded purchases across 51 reported transactions. Since December 2025, Krishnan has executed multiple sales totaling over $33.3 million, with the most concentrated activity occurring on March 4, 2026. On that date alone, he sold shares in 10 separate transactions ranging from $121,438 to $2.3 million, collectively amounting to approximately $6.4 million. These disposals followed earlier sales on December 4, 2025, including a $2.3 million transaction, and a series of February 27, 2026, filings related to derivative securities with no reported value changes. The transactions reveal an exclusive focus on KRYS, with no diversification across other companies. While derivative filings on February 27 included awards (code A) and option exercises (code M) with zero reported value, the accompanying sales (code F) that day totaled $8.4 million across five transactions, the largest being $3.3 million. The absence of any buy transactions—both in recent activity and historical filings—suggests a sustained disposition strategy rather than periodic rebalancing. The sales, executed at varying scales, indicate systematic liquidation rather than isolated disposals, though the filings do not specify whether these were prearranged trading plans.